drugset / Trial / NCT00798252
Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To determine safety and maximum tolerated dose of brivanib alaninate when administered in combination with capecitabine, doxorubicin, ixabepilone, docetaxel and paclitaxel chemotherapy to subjects with advanced or metastatic solid tumors
Timeline
- Start
- 2009-03
- Primary completion
- 2015-05
- Completion
- 2015-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brivanib alaninate | Small molecule | 400 mg | Oral |
| Subject | Capecitabine | Small molecule | 850 mg/m2 | Oral |
| Subject | Docetaxel | Small molecule | 60 mg/m2 | — |
| Subject | Doxorubicin | Other / unclassified | 40 mg/m2 | — |
| Subject | Ixabepilone | Small molecule | 32 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 135 mg/m2 | — |